Evidence map›Paper›PMID 30068350›Full record

ArticleMolecular neurodegeneration2018

Transcriptional profiling of HERV-K(HML-2) in amyotrophic lateral sclerosis and potential implications for expression of HML-2 proteins.

Jens Mayer, Christian Harz, Laura Sanchez, Gavin C Pereira, Esther Maldener, Sara R Heras, Lyle W Ostrow, John Ravits, Ranjan Batra, Eckart Meese and 2 more

Open access · goldAbstract read
In one paragraph

Article in Molecular neurodegeneration, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 60 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. The Molecular Impacts of Retrotransposons in Development and Diseases.International journal of molecular sciences · 2023
    Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Retroviral Elements in Pathophysiology and as Therapeutic Targets for Amyotrophic Lateral Sclerosis.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 4 countries.

Jens MayerDepartment of Human Genetics, University of Saarland, Homburg, Germany. jens.mayer@uks.eu.ORCID 0000-0002-1090-5765
Christian HarzDepartment of Human Genetics, University of Saarland, Homburg, Germany.
Laura SanchezGENYO. Centre for Genomics and Oncological Research: Pfizer, University of Granada, Andalusian Regional Government, Granada, Spain.
Gavin C PereiraMcKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Esther MaldenerDepartment of Human Genetics, University of Saarland, Homburg, Germany.
Sara R HerasGENYO. Centre for Genomics and Oncological Research: Pfizer, University of Granada, Andalusian Regional Government, Granada, Spain.
Lyle W OstrowDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, 28217, USA.
John RavitsDepartment of Neurosciences, School of Medicine, UCSD, San Diego, CA, USA.
Ranjan BatraDepartment of Neurosciences, School of Medicine, UCSD, San Diego, CA, USA.
Eckart MeeseDepartment of Human Genetics, University of Saarland, Homburg, Germany.
Jose Luis García-PérezGENYO. Centre for Genomics and Oncological Research: Pfizer, University of Granada, Andalusian Regional Government, Granada, Spain.
John L GoodierMcKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA. jgoodier@jhmi.edu.
Saarland University · DEJohns Hopkins University · USUniversity of California San Diego · USPfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research · ESUniversidad de Granada · ESWestern General Hospital · GB

Funding

A role for endogenous retroelements in Aicardi-Goutieres SyndromeR21HD083915 · NICHD · JOHNS HOPKINS UNIVERSITY · PI GOODIER, JOHN LAWRENCE · 2016 to 2017
$449k
Exploring a role for LINE1 retrotransposons in neurodegenerative diseaseR03NS087290 · NINDS · JOHNS HOPKINS UNIVERSITY · PI GOODIER, JOHN LAWRENCE · 2014 to 2015
$162k
ALS Therapy Alliance 2013-F-067Eunice Kennedy Shriver National Institute of Child Health and Human Development 1R21HD083915-01A1European Research Council ERC-Consolidator ERC-STG-2012-233764Howard Hughes Medical Institute IECS-55007420NICHD NIH HHS R21 HD083915NINDS NIH HHS 1R03NS087290-01NINDS NIH HHS R03 NS087290Plan Nacional de I+D+I 2013-2016 FIS-FEDER-PI14/02152The Wellcome Trust-University of Edinburgh Institutional Strategic Support Fund ISFF2Wellcome Trust
6 · The paper itself

Abstract

backgroundAmyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder. About 90% of ALS cases are without a known genetic cause. The human endogenous retrovirus multi-copy HERV-K(HML-2) group was recently reported to potentially contribute to neurodegeneration and disease pathogenesis in ALS because of transcriptional upregulation and toxic effects of HML-2 Envelope (Env) protein. Env and other proteins are encoded by some transcriptionally active HML-2 loci. However, more detailed information is required regarding which HML-2 loci are transcribed in ALS, which of their proteins are expressed, and differences between the disease and non-disease states.

methodsFor brain and spinal cord tissue samples from ALS patients and controls, we identified transcribed HML-2 loci by generating and mapping HML-2-specific cDNA sequences. We predicted expression of HML-2 env gene-derived proteins based on the observed cDNA sequences. Furthermore, we determined overall HML-2 transcript levels by RT-qPCR and investigated presence of HML-2 Env protein in ALS and control tissue samples by Western blotting.

resultsWe identified 24 different transcribed HML-2 loci. Some of those loci are transcribed at relatively high levels. However, significant differences in HML-2 loci transcriptional activities were not seen when comparing ALS and controls. Likewise, overall HML-2 transcript levels, as determined by RT-qPCR, were not significantly different between ALS and controls. Indeed, we were unable to detect full-length HML-2 Env protein in ALS and control tissue samples despite reasonable sensitivity. Rather our analyses suggest that a number of HML-2 protein variants other than full-length Env may potentially be expressed in ALS patients.

conclusionsOur results expand and refine recent publications on HERV-K(HML-2) and ALS. Some of our results are in conflict with recent findings and call for further specific analyses. Our profiling of HML-2 transcription in ALS opens up the possibility that HML-2 proteins other than canonical full-length Env may have to be considered when studying the role of HML-2 in ALS disease.

Indexed as

Endogenous RetrovirusesAmyotrophic Lateral SclerosisGene Expression ProfilingHumansMembrane ProteinsProvirusesSuperantigensTranscriptomeMembrane ProteinsSuperantigensAmyotrophic lateral sclerosisEnvelope proteinGag proteinHERV-K(HML-2)Human endogenous retrovirusProvirusRetrotransposonReverse transcription

Identifiers

PMID30068350
PMCPMC6091006
OpenAlexW2886559270

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.